Capital Flow Monitor · Sponsors · CIK 1693764
RECODE THERAPEUTICS, INC.
1140 O'Brien Drive, Menlo Park, CA, 94025 · 408-585-1700
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$29.4M
Sold
$29.4M
% sold
100.0%
Investors
26
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | D ·current | 506(b) | $29.4M | $29.4M | 100.0% | 26 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Shehnaaz Suliman — Executive Officer / Director, Menlo Park, CA
-
Peter A. Thompson — Director, Menlo Park, CA
3 other raises
- OrbiMed Partners II, L.P. $1.78B of —
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
- Helen S. Kim — Director, Menlo Park, CA
- Edward Hurwitz — Director, Menlo Park, CA
- Rana Al-Hallaq — Director, Menlo Park, CA
-
Rakhshita Dhar — Director, Menlo Park, CA
2 other raises
- NextPoint Therapeutics, Inc. $33.7M of $48.7M · 69.2%
- SonoThera, Inc. $125.5M of $125.5M · 100.0%
-
Alan Colowick — Director, Menlo Park, CA
1 other raise
- Solve Therapeutics, Inc. $48.2M of $120.5M · 40.0%
- Patricia Millican — Director, Menlo Park, CA
- Dean Mitchell — Director, Menlo Park, CA
- Inai Park — Director, Menlo Park, CA
- Basheer Zada — Director, Menlo Park, CA
- David Lockhart — Executive Officer, Menlo Park, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.